Chiesi Farmaceutici discloses new DDR1 and DDR2 inhibitors
Oct. 14, 2022
Chiesi Farmaceutici SpA has patented discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis, particularly idiopathic pulmonary fibrosis (IPF).